Evercore ISI Group Downgrades Bionomics to In-Line, Lowers Price Target to $6
Evercore ISI Group analyst Joshua Schimmer downgrades Bionomics (NASDAQ:BNOX) from Outperform to In-Line and lowers the price target from $17 to $6.
All Focus Shifts To Bionomics’ PTSD Study After Anxiety Trial Disappoints
Bionomics Limited (NASDAQ:BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety…
Maxim Group Downgrades Synaptogenix to Hold
Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.
TD Securities Downgrades Louisiana-Pacific to Hold, Announces $72 Price Target
TD Securities analyst Sean Steuart downgrades Louisiana-Pacific (NYSE:LPX) from Buy to Hold and announces $72 price target.
MoffettNathanson Downgrades AT&T to Underperform
MoffettNathanson analyst Craig Moffett downgrades AT&T (NYSE:T) from Market Perform to Underperform.
Oppenheimer Downgrades Tesla to Perform
Oppenheimer analyst Colin Rusch downgrades Tesla (NASDAQ:TSLA) from Outperform to Perform.
HC Wainwright & Co. Downgrades Bionomics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Bionomics (NASDAQ:BNOX) from Buy to Neutral.
Baird Downgrades Maxar Technologies to Neutral, Raises Price Target to $53
Baird analyst Peter Arment downgrades Maxar Technologies (NYSE:MAXR) from Outperform to Neutral and raises the price target from $45 to $53.
Jefferies Downgrades Aerojet Rocketdyne Hldgs to Hold, Lowers Price Target to $58
Jefferies analyst Greg Konrad downgrades Aerojet Rocketdyne Hldgs (NYSE:AJRD) from Buy to Hold and lowers the price target from $62 to $58.
Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target
Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.